Company Overview of Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals, Inc. engages in the development of molecular imaging agents for the medical management of chronic human diseases. The company was founded in 2004 and is based in Philadelphia, Pennsylvania. As of December 20, 2010, Avid Radiopharmaceuticals, Inc. operates as a subsidiary of Eli Lilly and Company.
3711 Market Street
Philadelphia, PA 19104
Founded in 2004
Key Executives for Avid Radiopharmaceuticals, Inc.
Chief Scientific Advisor and Chairman of the Scientific Advisory Board
Vice President of Clinical Development
Vice President of Chemical Development and Manufacturing
Compensation as of Fiscal Year 2014.
Avid Radiopharmaceuticals, Inc. Key Developments
Eli Lilly & Co. and Avid Radiopharmaceuticals, Inc. Receive Positive Opinion from Committee for Medicinal Products for Human Use in Europe, Recommending Approval of Amyvid Solution as Diagnostic Tool for PET Imaging of Beta-Amyloid Plaque Density
Oct 19 12
Eli Lilly & Co. and Avid Radiopharmaceuticals, Inc. announced they received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe, recommending approval of Amyvid (Florbetapir F 18) solution for injection as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation. The positive opinion is now referred for final action to the European Commission, which has the authority to approve medicines for the European Union (EU). The Commission usually decides on CHMP recommendations within three months. Amyvid for intravenous use was approved by the U.S. Food and Drug Administration (FDA) in April 2012 and is supplied in 10 mL, 30 mL, or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F 18. Amyvid is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease. A positive Amyvid scan indicates moderate to frequent amyloid plaques are present; this amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries